ARIAD Presents Positive Phase 1/2 Trial Data on AP26113 in Patients with Non-Small Cell Lung Cancer at ECC 2013
September 28, 2013 at 09:29 AM EDT
ARIAD Pharmaceuticals (NASDAQ: ARIA ) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from
